Sovel reads the deviation narrative, the master batch record annotation, and the OOS investigation log — then proposes findings a named QU representative approves. The human-clearance record FDA Warning Letter 320-26-58 (April 2026) requires for AI-derived output. Autonomous-write competitors can't produce it.
OOS-2204 closes with a CAPA: "investigate root cause, update SOP, retrain operators." Eight months later, OOS-2811 opens with the same root-cause class on a sister batch. The CAPA-effectiveness review will catch it — six months from now, in the next QMS review cycle. The CAPA was the load-bearing artifact, and it didn't land.
A senior process scientist hand-marks the master batch record during a complex tech-transfer — "hold time at step 14 capped at 4hr per stability data, NOT 8hr." The annotation survives the batch, but doesn't make it into the next master revision. The next campaign uses 8hr. The annotation was the only governance against the stability-data limit.
Three OOS investigations in one quarter all close with "analyst error." The fourth investigation, conducted by a different QC supervisor, is the first to ask whether the four events share an upstream pattern (column packing, mobile-phase prep, instrument calibration drift). The first three closures locked the wrong root cause. The QU approved them.
FDA cGMP and electronic-records requirements Sovel maps against — Part 11 closed-system controls, Part 211 production-record review and CAPA effectiveness, and the April 2026 FDA Warning Letter (320-26-58) that established the AI-output human-clearance precedent.
Reviewer inbox surfacing a BATCH-4451 §211.180(e) production-record gap plus three additional pharma findings — a repeat OOS that bypassed CAPA, a master-batch annotation lost between revisions, and a pattern of investigations closed as 'analyst error' that share an upstream cause. Each row is a knowledge-risk finding Sovel proposes; the named QU representative approves, defers, or rejects. Approval emits a verify-in-place record that satisfies the FDA WL 320-26-58 human-clearance requirement and the 21 CFR §11.10(e) audit-trail elements.
Two-week scoped engagement against one eQMS or batch-record export. One named Sovel reviewer, one substrate scan, one auditable bundle — mapped to the 21 CFR Part 11 + Part 211 sections your QU already audits against, and architected to satisfy the April 2026 FDA AI-clearance precedent.